comparemela.com

Latest Breaking News On - Secondary progressive multiple sclerosis - Page 2 : comparemela.com

Phase 2 Clinical Trial For SPMS With Intranasal Monoclonal Antibody

Tiziana Life Sciences expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis that’s administered through the nose.

Tiziana life sciencesSecondary progressive multiple sclerosisEmission tomographyModified fatigue impact scaleExpanded disability status scaleFoot walk testNeuroqol fatigue

Tiziana Life Sciences : Updated Interim Results for the Six Months Ended 30 June 2023 - Form 6-K -December 29, 2023 at 04:39 pm EST

Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 - Tiziana Life Sciences, Ltd. , a biotechnology company developing breakthrough.

United statesUnited kingdomCity ofTanuja chitnisMatthew davisMonte carloGabriele cerroneSaef izzyWilliama haseltineWilliama clementiPaul spencerIrina kofflerHoward weinerTiziana life sciencesLifesci advisorsPharma ltd

Tiziana Life Sciences : Interim Results for the Six Months Ended 30 June 2023 863 7 KB -December 29, 2023 at 04:39 pm EST

Tiziana Life Sciences Ltd Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 -.

United statesGabriele cerroneTanuja chitnisMatthew davisIrina kofflerHoward weinerSaef izzyWilliama haseltinePaul spencerWilliama clementiTiziana life sciencesLifesci advisorsInternational conference on alzheimerInvestment in related partyTiziana life sciences ltdBusiness development

Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal…

This month, Tiziana Life Sciences TLSA expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary…

Tiziana life sciencesSecondary progressive multiple sclerosisHave few effectiveReaking news

Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab - Tiziana Life Sciences (NASDAQ:TLSA)

This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s administered through the nose.

Tanuja chitnisGabriele cerroneProfessor of neurology at harvard medical schoolTiziana lifeSecondary progressive multiple sclerosisHave few effective treatment optionsHave even fewerDifference in patientEmission tomographyModified fatigue impact scalePrincipal investigatorHarvard medical schoolExpanded disability status scaleFoot walk testNeuroqol fatigueTiziana founder gabriele

vimarsana © 2020. All Rights Reserved.